FDA approves denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) – Fresenius Kabi
Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the… read more.
